Kadowaki T, Hagura R, Kajinuma H, Kuzuya N, Yoshida S
Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan.
Diabetes Care. 1983 Sep-Oct;6(5):468-71. doi: 10.2337/diacare.6.5.468.
The incidence and risk factors of chlorpropamide-induced hyponatremia were assessed in diabetic outpatients. In 176 chlorpropamide-treated patients, 11 (6.3%) exhibited hyponatremia (serum sodium less than or equal to 129 meq/L) during the mean follow-up period of 7.4 yr. In contrast, only one (0.6%) developed hyponatremia in 162 tolbutamide- or glibenclamide-treated patients (P less than 0.005). Moreover, administration to elderly patients and combination with thiazide diuretics were regarded as significantly potent risk factors for the development of hyponatremia in patients receiving chlorpropamide.
对糖尿病门诊患者中氯磺丙脲所致低钠血症的发病率及危险因素进行了评估。在176例接受氯磺丙脲治疗的患者中，在平均7.4年的随访期内，有11例（6.3%）出现低钠血症（血清钠≤129 meq/L）。相比之下，在162例接受甲苯磺丁脲或格列本脲治疗的患者中，只有1例（0.6%）出现低钠血症（P<0.005）。此外，老年患者用药以及与噻嗪类利尿剂联用被视为接受氯磺丙脲治疗的患者发生低钠血症的显著危险因素。
